[Long-term therapy of a metastasizing pancreatic vipoma using the somatostatin derivative octreotide].
A patient with metastatic VIP-producing pancreatic tumor was successfully treated with subcutaneous octreotide, an analogue of somatostatin, for more than 4 years. The profuse diarrhea was rapidly controlled and the plasma concentrations of the hormones (VIP, neurotensin, gastrin, pancreatic polypeptide) fell to nearly normal within 2 months. Because of asymptomatic increase in tumor size, we added chemotherapy 2 years later. Since the drug is rapidly effective and well tolerated, it will probably become the therapy of choice in this syndrome.
Flückiger
A
A
Medizinische Abteilung, Spital Grenchen.
Schlup
P
P
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary*; D008297:Male; D009496:Neurotensin / Q000097:blood; D015282:Octreotide / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000473:pathology*; D013311:Streptozocin / Q000008:administration & dosage; D014660:Vasoactive Intestinal Peptide / Q000097:blood; D003969:Vipoma / Q000188:drug therapy / Q000473:pathology / Q000556:secondary*
D014660:Vasoactive Intestinal Peptide; D009496:Neurotensin; D013311:Streptozocin; D015282:Octreotide; D005472:Fluorouracil
Langzeittherapie eines metastasierenden Pankreas-Vipoms mit dem Somatostatinderivat Octreotid.